Error in Financial Disclosure in: Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005): Age, Dose, and Sex Effects on Immune Responses FREE

Error in Financial Disclosure. In the Original Investigation by Engler et al titled “Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005): Age, Dose, and Sex Effects on Immune Responses” published in the December 8/22, 2008 issue of the Archives (2008;168(22):2405-2414), an error occurred in the Financial Disclosure on page 2413. The Financial Disclosure should have read as follows:

“Financial Disclosure: Dr Keitel has received research support from Protein Sciences Inc and Novartis Vaccines. Dr Nichol has served as a consultant for the influenza vaccine manufacturers sanofi pasteur, GlaxoSmithKline Biologicals, CSL Biotherapies, Novartis, and MedImmune and has received research funding from sanofi pasteur and GlaxoSmithKline Biologicals. Dr Treanor has received research support from Protein Sciences, Merck, Wyeth, GlaxoSmithKline, Antigen Express, Mercia Pharma, VaxInnate, Ligocyte, Sanofi, and CSL Biotherapies; has served as a consultant/scientific advisory board member for AlphaVax, Epimmune, Dynavax, Immune Targeting Systems, Pulmatrix, Powdermed, PaxVax, and Toyama; and has served as a Data Safety Monitoring Board member for Medimmune and Novavax.”